GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzinova AB (OSTO:ALZ) » Definitions » Construction In Progress

Alzinova AB (OSTO:ALZ) Construction In Progress : kr0.00 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Alzinova AB Construction In Progress?


Alzinova AB Construction In Progress Historical Data

The historical data trend for Alzinova AB's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzinova AB Construction In Progress Chart

Alzinova AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial - - - - -

Alzinova AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alzinova AB Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Alzinova AB (OSTO:ALZ) Business Description

Traded in Other Exchanges
Address
Pepparedsleden 1, Molndal, SWE, SE-431 83
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is also engaged in development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody. The product is in clinical development as a therapeutic vaccine for the treatment of Alzheimer's.

Alzinova AB (OSTO:ALZ) Headlines

No Headlines